Close Menu

NEW YORK (360Dx) – Indivumed and Flagship Biosciences today announced a partnership to expand their tissue-based biomarker development capabilities and clinical services to support advanced oncology diagnostics.

Under the terms of the agreement, the companies will offer services that combine Flagship’s experience in biomarker development and Indivumed’s multiplex immunohistochemistry assay development capabilities.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.